Skip to main content
main-content
Erschienen in: Zeitschrift für Rheumatologie 10/2016

31.10.2016 | Idiopathische thrombozytopenische Purpura | Leitthema

Einsatz von Immunglobulinen

verfasst von: Prof. Dr. T. Witte

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Intravenöse Immunglobuline (IVIG) haben multiple Wirkmechanismen in der Entzündungshemmung. Sie können daher bei vielen Autoimmunerkrankungen eingesetzt werden.

Ziel der Arbeit

Es erfolgt die Beschreibung der Studienlage zum Einsatz von IVIG bei rheumatologischen Erkrankungen.

Methoden

Durchgeführt wurden eine selektive Literaturrecherche und -aufarbeitung zum Thema Wirkmechanismen und Effizienz von IVIG bei rheumatologischen Erkrankungen.

Ergebnisse und Diskussion

Die Therapie mit IVIG hat einen breiten Wirkmechanismus und kann daher bei fast allen Autoimmunerkrankungen Besserungen bringen. Besonders häufig wird IVIG bei den Erkrankungen Immunthrombozytopenie, Kawasaki-Syndrom und den idiopathischen Myositiden eingesetzt. Selten kann IVIG auch bei systemischem Lupus erythematodes, Sjögren-Syndrom mit Neuropathien, katastrophalem Antiphospholipidsyndrom, Sklerodermie, ANCA („antineutrophil cytoplasmic antibody“)-assoziierten Vaskulitiden, Pyoderma gangraenosum und Skleromyxödem indiziert sein. Schwere Nebenwirkungen sind selten. Angesichts der hohen Kosten wird die Therapie in der Regel aber nur in Notfallsituationen, beim Versagen von vorher durchgeführten Standardtherapien oder bei schweren Infektionen und somit Kontraindikation gegen eine Immunsuppression eingesetzt.
Literatur
1.
Zurück zum Zitat Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104(Suppl 1):10–21 PubMed Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104(Suppl 1):10–21 PubMed
2.
Zurück zum Zitat Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758–765 CrossRefPubMed Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758–765 CrossRefPubMed
3.
Zurück zum Zitat Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55:505–509 CrossRefPubMedPubMedCentral Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55:505–509 CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Carrock-Sewell WA, Kerr J, Behr-Gross ME, Peter HH (2014) European consensus proposal for immunoglobulin therapies. Eur J Immunol 44:2207–2214 CrossRef Carrock-Sewell WA, Kerr J, Behr-Gross ME, Peter HH (2014) European consensus proposal for immunoglobulin therapies. Eur J Immunol 44:2207–2214 CrossRef
5.
Zurück zum Zitat Cervera R, Rodríguez-Pintó I, Espinosa G, Task Force on Catastrophic Antiphospholipid Syndrome (2014) Catastrophic antiphospholipid syndrome: task force report summary. Lupus 23:1283–1285 CrossRefPubMed Cervera R, Rodríguez-Pintó I, Espinosa G, Task Force on Catastrophic Antiphospholipid Syndrome (2014) Catastrophic antiphospholipid syndrome: task force report summary. Lupus 23:1283–1285 CrossRefPubMed
6.
Zurück zum Zitat Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S (2002) Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46:467–474 CrossRefPubMed Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S (2002) Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46:467–474 CrossRefPubMed
7.
Zurück zum Zitat Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, Eymard B (2002) Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58:326 CrossRefPubMed Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, Eymard B (2002) Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58:326 CrossRefPubMed
8.
Zurück zum Zitat Cummins DL, Anhalt GJ, Monahan T, Meyerle JH (2007) Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol 157:1235–1239 CrossRefPubMed Cummins DL, Anhalt GJ, Monahan T, Meyerle JH (2007) Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol 157:1235–1239 CrossRefPubMed
9.
Zurück zum Zitat Dalakas MC (2002) Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59(12 Suppl 6):S13–S21 CrossRefPubMed Dalakas MC (2002) Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59(12 Suppl 6):S13–S21 CrossRefPubMed
10.
Zurück zum Zitat Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000 CrossRefPubMed Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000 CrossRefPubMed
11.
Zurück zum Zitat Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323–327 CrossRefPubMed Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323–327 CrossRefPubMed
12.
Zurück zum Zitat Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48:712–716 CrossRefPubMed Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48:712–716 CrossRefPubMed
13.
Zurück zum Zitat Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A (2009) Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 9:124–127 CrossRefPubMed Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A (2009) Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 9:124–127 CrossRefPubMed
14.
Zurück zum Zitat Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sørensen P, Udd B, EFNS (2008) EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 15:893–908 CrossRefPubMed Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sørensen P, Udd B, EFNS (2008) EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 15:893–908 CrossRefPubMed
15.
Zurück zum Zitat Enk A, European Dermatology Forum Guideline Subcommittee (2009) Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 19:90–98 PubMed Enk A, European Dermatology Forum Guideline Subcommittee (2009) Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 19:90–98 PubMed
16.
Zurück zum Zitat Fortin PM, Tejani AM, Bassett K, Musini VM (2013) Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database Syst Rev 1:CD007057 Fortin PM, Tejani AM, Bassett K, Musini VM (2013) Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database Syst Rev 1:CD007057
19.
Zurück zum Zitat Hundt M, Manger K, Dörner T, Grimbacher B, Kalden P, Rascu A, Weber D, Burmester GR, Peter HH, Kalden JR, Schmidt RE (2000) Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 39:1301–1302 CrossRef Hundt M, Manger K, Dörner T, Grimbacher B, Kalden P, Rascu A, Weber D, Burmester GR, Peter HH, Kalden JR, Schmidt RE (2000) Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 39:1301–1302 CrossRef
20.
Zurück zum Zitat Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231 CrossRefPubMed Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231 CrossRefPubMed
21.
Zurück zum Zitat Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, Lockwood CM (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439 CrossRefPubMed Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, Lockwood CM (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439 CrossRefPubMed
22.
Zurück zum Zitat Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755 CrossRefPubMed Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755 CrossRefPubMed
23.
Zurück zum Zitat Kerr J, Quinti I, Eibl M, Chapel H, Späth PJ, Carrock Sewell WA et al (2014) Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol 5:629 CrossRefPubMedPubMedCentral Kerr J, Quinti I, Eibl M, Chapel H, Späth PJ, Carrock Sewell WA et al (2014) Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol 5:629 CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Kreuter A, Reich-Schupke S, Stücker M, Stücker M, Altmeyer P, Gambichler T (2008) Intravenous immunoglobulin for pyoderma gangrenosum. Br J Dermatol 158:856–857 CrossRefPubMed Kreuter A, Reich-Schupke S, Stücker M, Stücker M, Altmeyer P, Gambichler T (2008) Intravenous immunoglobulin for pyoderma gangrenosum. Br J Dermatol 158:856–857 CrossRefPubMed
25.
Zurück zum Zitat Kumar N, Rodriguez M (2004) Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler 10:85–86 CrossRefPubMed Kumar N, Rodriguez M (2004) Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler 10:85–86 CrossRefPubMed
26.
Zurück zum Zitat Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D’Cruz D, Guillevin L, Harper L, Jayne D, Luqmani R, Mooney J, Scott D, BSR and BHPR Standards, Guidelines and Audit Working Group (2007) BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 46:1615–1616 CrossRefPubMed Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D’Cruz D, Guillevin L, Harper L, Jayne D, Luqmani R, Mooney J, Scott D, BSR and BHPR Standards, Guidelines and Audit Working Group (2007) BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 46:1615–1616 CrossRefPubMed
27.
Zurück zum Zitat Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y (1999) A study of 20 SLE patients with intravenous immunoglobulin-clinical and serological response. Lupus 8:705–712 CrossRefPubMed Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y (1999) A study of 20 SLE patients with intravenous immunoglobulin-clinical and serological response. Lupus 8:705–712 CrossRefPubMed
28.
Zurück zum Zitat Levy Y, Uziel Y, Zandman GG, Amital H, Sherer Y, Langevitz P, Goldman B, Shoenfeld Y (2003) Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 62:1221–1223 CrossRefPubMedPubMedCentral Levy Y, Uziel Y, Zandman GG, Amital H, Sherer Y, Langevitz P, Goldman B, Shoenfeld Y (2003) Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 62:1221–1223 CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M, Rustin MH (2000) Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 43:403–408 CrossRefPubMed Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M, Rustin MH (2000) Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 43:403–408 CrossRefPubMed
30.
Zurück zum Zitat Lutz HU, Stammler P, Bianchi V, Trüeb RM, Hunziker T, Burger R, Jelezarova E, Späth PJ (2004) Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103:465–472 CrossRefPubMed Lutz HU, Stammler P, Bianchi V, Trüeb RM, Hunziker T, Burger R, Jelezarova E, Späth PJ (2004) Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103:465–472 CrossRefPubMed
31.
Zurück zum Zitat Matzdorff A, Giagounidis A, Greinacher A, Hiller E, Kiefel V, Müller-Beissenhirtz H, Ostermann H, Rummel M, Sachs UJ, Salama A (2010) Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH. Onkologie 33(Suppl 3):2–20 CrossRefPubMed Matzdorff A, Giagounidis A, Greinacher A, Hiller E, Kiefel V, Müller-Beissenhirtz H, Ostermann H, Rummel M, Sachs UJ, Salama A (2010) Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH. Onkologie 33(Suppl 3):2–20 CrossRefPubMed
33.
Zurück zum Zitat Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, Katsuno M, Fujita A, Aiba I, Ogata A, Saito T, Asakura K, Yoshida M, Hirayama M, Sobue G (2005) The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain 128:2518–2534 CrossRefPubMed Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, Katsuno M, Fujita A, Aiba I, Ogata A, Saito T, Asakura K, Yoshida M, Hirayama M, Sobue G (2005) The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain 128:2518–2534 CrossRefPubMed
34.
Zurück zum Zitat Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341–347 CrossRefPubMed Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341–347 CrossRefPubMed
35.
Zurück zum Zitat Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I (2003) Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 4:CD004000 Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I (2003) Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 4:CD004000
36.
Zurück zum Zitat Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA (2015) Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol 42:236–242 CrossRefPubMed Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA (2015) Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol 42:236–242 CrossRefPubMed
37.
Zurück zum Zitat Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH (2016) Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford) 55:115–119 CrossRef Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH (2016) Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford) 55:115–119 CrossRef
38.
Zurück zum Zitat Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL (1995) Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101:2–7 CrossRefPubMedPubMedCentral Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL (1995) Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101:2–7 CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484–486 CrossRefPubMed Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484–486 CrossRefPubMed
40.
Zurück zum Zitat Sherer Y, Kuechler S, Jose Scali J, Rovensky J, Levy Y, Zandman-Goddard G, Shoenfeld Y (2008) Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 10:55–57 PubMed Sherer Y, Kuechler S, Jose Scali J, Rovensky J, Levy Y, Zandman-Goddard G, Shoenfeld Y (2008) Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 10:55–57 PubMed
41.
Zurück zum Zitat Soueidan SA, Dalakas MC (1993) Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 43:876–879 CrossRefPubMed Soueidan SA, Dalakas MC (1993) Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 43:876–879 CrossRefPubMed
42.
Zurück zum Zitat Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, Suda T, Chida K (2009) Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187:201–206 CrossRefPubMed Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, Suda T, Chida K (2009) Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187:201–206 CrossRefPubMed
43.
Zurück zum Zitat Takehara K, Ihn H, Sato S (2013) A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 31(2 Suppl 76):151–156 PubMed Takehara K, Ihn H, Sato S (2013) A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 31(2 Suppl 76):151–156 PubMed
44.
Zurück zum Zitat Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, Akiyama K (2004) Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92:80–87 CrossRefPubMed Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, Akiyama K (2004) Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92:80–87 CrossRefPubMed
45.
Zurück zum Zitat Walter MC, Lochmüller H, Toepfer M, Schlotter B, Reilich P, Schröder M, Müller-Felber W, Pongratz D (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247:22–28 CrossRefPubMed Walter MC, Lochmüller H, Toepfer M, Schlotter B, Reilich P, Schröder M, Müller-Felber W, Pongratz D (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247:22–28 CrossRefPubMed
Metadaten
Titel
Einsatz von Immunglobulinen
verfasst von
Prof. Dr. T. Witte
Publikationsdatum
31.10.2016

Weitere Artikel der Ausgabe 10/2016

Zeitschrift für Rheumatologie 10/2016 Zur Ausgabe

Mitteilungen der DGRh

Mitteilungen der DGRh

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.